Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPOXX and JYNNEOS Drug-Vaccine Interaction Study
NCT04957485Phase 2Active, not recruiting
- Sponsor
- SIGA Technologies
- Start
- Apr 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tecovirimat in smallpox, sponsored by SIGA Technologies. Started Apr 2022; status: active, not recruiting.
02
Drugs
tecovirimat
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT04957485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04957485.